Drug Store News - Warner Chilcott files ANDA for terazosin hydrochloride capsules
Warner Chilcott PLC has filed an abbreviated new drug application with the FDA for an AB rateable form of terazosin hydrochloride capsules, said to be a bioequivalent of Abbott Laboratories’ Hytrin alpha blocker.
Related Results
Common prostate drug is ineffective - Hytrin works better - Hytrin vs ProscarMylan receives approval for generic HytrinTorPharm Hytrin ANDA clearedTrust, E-innovation and Leadership in ChangeForeign Banks in United States Since World War II: A Useful Fringe
COPYRIGHT 1998 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2008 Gale, Cengage Learning
